Copyright
©The Author(s) 2016.
World J Gastroenterol. Sep 7, 2016; 22(33): 7569-7578
Published online Sep 7, 2016. doi: 10.3748/wjg.v22.i33.7569
Published online Sep 7, 2016. doi: 10.3748/wjg.v22.i33.7569
Table 3 Characteristics of the 8 patients with hepatocellular carcinoma development
| Age (yr) | Sex | Interval (yr) | F | A | Albumin (g/dL) | ALT (IU/L) | Platelet count (× 104/mL) | AKR1B10 | |
| 1 | 62 | F | 1.0 | 2 | 2 | 4.0 | 199 | 10.3 | 60% |
| 2 | 69 | F | 1.8 | 3 | 2 | 3.3 | 60 | 9.9 | 7% |
| 3 | 61 | M | 2.8 | 2 | 2 | 4.4 | 135 | 10.3 | 13% |
| 4 | 65 | M | 3.8 | 4 | 3 | 3.4 | 88 | 9.0 | 52% |
| 5 | 49 | M | 4.3 | 3 | 2 | 3.8 | 209 | 7.9 | 38% |
| 6 | 56 | M | 4.9 | 3 | 2 | 4.2 | 156 | 19.3 | 9% |
| 7 | 57 | M | 5.8 | 3 | 2 | 4.2 | 157 | 14.7 | 16% |
| 8 | 71 | M | 9.0 | 3 | 2 | 3.7 | 31 | 17.9 | 0% |
- Citation: Murata A, Genda T, Ichida T, Amano N, Sato S, Tsuzura H, Sato S, Narita Y, Kanemitsu Y, Shimada Y, Hirano K, Iijima K, Wada R, Nagahara A, Watanabe S. Pretreatment AKR1B10 expression predicts the risk of hepatocellular carcinoma development after hepatitis C virus eradication. World J Gastroenterol 2016; 22(33): 7569-7578
- URL: https://www.wjgnet.com/1007-9327/full/v22/i33/7569.htm
- DOI: https://dx.doi.org/10.3748/wjg.v22.i33.7569